Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc raises FY 2014 guidance; gives Q2 2014 guidance, EPS guidance above analysts' estimates


Wednesday, 7 May 2014 09:00am EDT 

Allergan Inc:Now expects FY 2014 total product net sales between $6.775 and $7.00 billion.FY 2014 non-GAAP diluted earnings per share attributable to stockholders between $5.64 and $5.73.FY 2014 revenue of $6.870 billion and EPS of $4.75 - Thomson Reuters I/B/E/S.Expects Q2 2014 total product net sales between $1.725 and $1.80 billion.Q2 2014 non-GAAP diluted earnings per share attributable to stockholders between $1.41 and $1.44.Q2 2014 revenue of $1.745 billion and EPS of $1.37 - Thomson Reuters I/B/E/S. 

Company Quote

167.67
-2.3 -1.35%
1:34pm EDT